Growth hormone replacement and the risk of malignancy in children with neurofibromatosis

Area of Science:

• Pediatrics
• Endocrinology
• Growth Disorders

Background:

• Idiopathic short stature (ISS) is a condition characterized by short height without identifiable medical or hormonal causes.
• Growth hormone (GH) therapy is a potential treatment option for children with ISS to improve final adult height.
• Long-term outcomes of GH treatment in ISS require further investigation.

Purpose of the Study:

• To evaluate the efficacy of growth hormone (GH) treatment in achieving normal adult height in children with idiopathic short stature (ISS).
• To assess the safety and long-term effects of GH therapy in this pediatric population.

Main Methods:

• A cohort of children diagnosed with idiopathic short stature (ISS) received daily subcutaneous injections of recombinant human growth hormone (rhGH).
• Treatment duration and dosage were individualized based on patient response and clinical guidelines.
• Final adult height was compared to predicted height and population norms.

Main Results:

• Children treated with GH achieved a significantly improved final adult height compared to their predicted height.
• The treatment was generally well-tolerated, with no major adverse events reported.
• Height standard deviation scores (SDS) at final height were substantially improved.

Conclusions:

• Growth hormone (GH) therapy is an effective treatment for improving final height in children with idiopathic short stature (ISS).
• GH treatment offers a viable therapeutic option for optimizing growth outcomes in children with unexplained short stature.
• Long-term safety and efficacy support the use of GH in selected pediatric patients.